Detalles de la búsqueda
1.
Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis.
Cancer Manag Res
; 11: 1289-1297, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30799955
2.
Promising long-term health-related quality of life after high-dose-rate brachytherapy boost for localized prostate cancer.
Int J Radiat Oncol Biol Phys
; 69(3): 662-70, 2007 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17499452
3.
Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations.
Urol Oncol
; 35(9): 541.e15-541.e22, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28623071
4.
Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
Int J Radiat Oncol Biol Phys
; 60(1): 51-9, 2004 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15337539
5.
Use of the Charlson combined comorbidity index to predict postradiotherapy quality of life for prostate cancer patients.
Int J Radiat Oncol Biol Phys
; 81(4): 997-1004, 2011 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20932681
6.
Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up.
Acta Oncol
; 46(7): 909-17, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17917823
7.
Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: a prospective assessment of acute and late treatment toxicity.
Acta Oncol
; 44(6): 633-43, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16165923
Resultados
1 -
7
de 7
1
Próxima >
>>